1325 Boylston Street
About Decibel TherapeuticsDecibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. Founded by the world’s preeminent experts in hearing loss, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and is headquartered in Cambridge, Mass.
President and CEO: Steven Holtzman
CMO: Leslie Shinobu, M.D., Ph.D.
Vice President, Pharmacology: Ada Silos-Santiago, Ph.D.
October 15, 2015: $52 Million Series A From GlaxoSmithKline, SR One and Third Rock Ventures.
25 articles with Decibel Therapeutics
Biotech and pharma companies tap new members of executive leadership teams and boards.
Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors
Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, announced the appointment of Christine Poon to its board of directors.
4G Clinical today announced a partnership with Decibel Therapeutics to enable complex trial designs for the development of novel therapies for hearing and balance disorders.
2/8/2019In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology from February 9-13, 2019.
Decibel Therapeutics Bolsters Leadership Team with Appointments of Chief Medical Officer and Chief Operating Officer
Decibel Therapeutics today announced the appointment of leading otolaryngologist Dr.
Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear
Decibel Therapeutics and Cocoon Biotech announced a research collaboration to apply Cocoon's proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders
Among life on earth, mammals are some of the only creatures that can’t regenerate damaged hearing. Birds, frogs, fish, they all have the ability to regenerate sensory hair cells after they’re damaged.
Medidata and Decibel Therapeutics Announce Multi-Year Collaboration in Support of Clinical Development for Hearing Loss, Tinnitus, and Balance Disorders
Decibel to Unify Data and Scale with Medidata Cloud
Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell
Decibel Therapeutics researchers and Johns Hopkins University professors Ulrich Mueller, Ph.D. (a Decibel co-founder) and Dwight Bergles, Ph.D., published the results of groundbreaking research which may hold the key to discovering new mechanisms behind hearing disorders and tinnitus. C
Venture capitalists are flexing their muscles today with the significant support of pharma and biotech companies.
Decibel Therapeutics announced that it has raised $55M in a Series C financing.
Decibel Therapeutics Presents at 2018 Annual Association for Research in Otolaryngology (ARO) Meeting
Decibel scientists have been selected to present four posters and deliver two podium presentations at the 41st Annual ARO Midwinter Meeting in San Diego, Calif.
Regeneron and Decibel scientists will be working together, shoulder to shoulder, on project teams beginning at the earliest stages of research.
Decibel Therapeutics Release: Biotech Expands Leadership Team With World-Class Bioinformatics Scientist; Appoints Three New Members To Its Board Of Directors
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.